# Parabilis Medicines

Source: https://onco.cc/companies/parabilis-medicines/  
OnCo record `parabilis-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Parabilis Medicines makes stabilised peptides, small protein fragments locked into a helix so they can enter cells and grip cancer proteins that ordinary pills cannot. Its lead medicine, zolucatetide, blocks the beta-catenin signal behind desmoid tumours, and a phase 3 trial is planned for 2027.

## Summary

Parabilis Medicines, Inc. (Nasdaq: PBLS), formerly FOG Pharmaceuticals (FogPharma), is a Cambridge, Massachusetts company founded in 2015 on technology in-licensed from the laboratory of Greg Verdine. Its Helicon platform produces stabilised helical peptides engineered to reach intracellular proteins with flat surfaces that small molecules and antibodies struggle to bind. The lead programme, zolucatetide, is described as the first drug to directly target the beta-catenin:TCF interaction and is in phase 1/2 development for desmoid tumours, familial adenomatous polyposis, hepatocellular carcinoma, colorectal cancer and rare Wnt/beta-catenin-driven tumours; the company plans a global registrational phase 3 trial in desmoid tumours in the first half of 2027. Preclinical programmes include an ERG degrader in IND-enabling studies and an ARON degrader against the active androgen receptor, both for prostate cancer, and beta-catenin degraders. The company raised over USD 800 million privately from investors including ARCH Venture Partners, RA Capital, Fidelity, GV and venBio, and listed on the Nasdaq Global Select Market in June 2026, selling 33.5 million shares at USD 20.00.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: FogPharma; FOG Pharmaceuticals
- HQ: Cambridge, MA
- Type: biotech
- Website: https://parabilismed.com/
- Ticker: PBLS

## Notes

- Included as a company that went public in the window and was not in the corpus; it was founded in 2015, before the window. Founding year, ticker, address and pipeline are taken from the S-1/A (CIK 0001657677) and the 424B4 prospectus. Zolucatetide is a stabilised peptide rather than a drug conjugate, so no peptide technology is linked; the degrader link rests on its preclinical ERG, androgen receptor and beta-catenin degraders. Updated phase 1/2 zolucatetide results were announced by the company but not read for this record.

## Sources

- Official website: https://parabilismed.com/
- Investor relations: https://investors.parabilismed.com/
- SEC EDGAR: IPO prospectus (424B4), June 2026: https://www.sec.gov/Archives/edgar/data/1657677/000119312526265983/pbls_424b4.htm
- SEC EDGAR: S-1/A registration statement: https://www.sec.gov/Archives/edgar/data/1657677/000119312526262880/ck0001657677-20260609.htm
- Second quarter 2026 results: https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-reports-second-quarter-2026-financial

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/), [Familial adenomatous polyposis-associated colorectal cancer](https://onco.cc/cancers/fap-associated-colorectal-cancer/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [CTNNB1](https://onco.cc/targets/ctnnb1/), [ERG](https://onco.cc/targets/erg/)
- companies: [ARCH Venture Partners](https://onco.cc/companies/arch-venture-partners/), [GV (Google Ventures)](https://onco.cc/companies/gv/), [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/parabilis-medicines.json